You are viewing a single comment's thread from:

RE: $600 EpiPen 2-Pack for Anaphylactic Shock has ONE MORE Competitor!

in #health • 7 years ago

Teva Pharmaceutical (TEVA) has partnered with Antares Pharmaceuticals (ATRS) and plan to release an EpiPen alternative in 2017. Once Teva gets their application in order and then the FDA approves it, EpiPen prices will drop like a rock.

7 years ago in #health by
$0.42
  • Past Payouts $0.42, 0.00 TRX
  • - Author $0.32, 0.00 TRX
  • - Curators $0.10, 0.00 TRX
1 vote
Reply 1
Sort:  
  • Trending
    • [-]
     7 years ago 

    We'll see... they've still got to get past the FDA. But thank you for bringing up another potential competitor coming down the pike!

    The biggest holdup so far has been the FDA. The FDA previously issued a CRL for Teva's submission, asking for additional information from the companies in order to be able to approve the ANDA. Investors in Antares are beholden to how quickly Teva will be able to resubmit the application. After the receipt of the CRL, Teva admitted that there were certain 'major deficiencies' in the application. This puts the timeline for approval into 2017. The timeline could be even later if there is any delay in fulfilling the FDA's requirements. Teva will need to move forward as quickly as possible in order to get its generic EpiPen approved.

    Link: Antares Pharmaceuticals: The Stock To Buy On EpiPen Issues

    $0.00
      Reply

      Coin Marketplace

      STEEM 0.17
      TRX 0.16
      JST 0.029
      BTC 60323.94
      ETH 2395.54
      USDT 1.00
      SBD 2.54